‘Sunshine Genetics Act' aims to advance care and research for rare diseases
Dubbed the 'Sunshine Genetics Act' Representative Anderson, R-Palm Harbor, wants to improve early diagnosis and treatment of rare diseases in newborns.
'It's like roulette': Pinellas hotel owner concerned over abrupt deadline for FEMA housing help
After unanimous bipartisan support and positive debate, House Bill 907 passed its first committee stop, with three more committee stops to go. Anderson is already looking to expand the reach of the rare disease pilot program.
'There's as many as 10,000 of these rare diseases. Very few of them have actionable treatments, but one of the really exciting things about Sunshine Genetics is that we'll be able to screen for as many as 600 of these conditions that do have actionable treatments,' Anderson said.
The bill would launch a pilot program offering genetic testing for newborns, in addition to the state's existing screening program. It would also establish a network of clinical academic research professionals, children's hospitals, and Florida universities to advance research, diagnosis, and treatment.
Amderson shared with 8 On Your Side that there are two different funding components being proposed right now. The first is a $5 million recurring funding for the Florida Institute for Pediatric Rare Diseases at FSU. They'll receive funding and support from the state to continue their research efforts and to continue building out their pediatric clinical Health Center to support their CLIA certified lab.
The other component is a onetime funding of $20 million specifically to watch the Sunshine Genetics pilot program.
'The inspiration comes from my son Andrew, he unfortunately passed away when he was four years old. He had a very rare, what they call an ultra-rare genetic disorder, called Tay Sachs Disease and there's no treatment for that,' Anderson said.
With personal ties to this initiative, Anderson knows firsthand the heartbreaking impacts of losing a child to a rare disease.'Being involved so much with these families is a little bit of a double-edged sword for me, and I say that because it's hard for me personally to interact with them because I understand what they're going through. I can relate to it. I am one of those parents and I always will be. But that's also the motivation, that's why we do it,' Anderson said.
With high hopes the legislation will continue to garner support, Anderson says this program is a step in ending the diagnostic odyssey so many Floridians find themselves in.
'Representative Anderson, you poured your heart and soul into this bill,' said State Representative Dean Black, R-Jacksonville. 'Seldom do we get a chance to truly change lives and thereby change the world, Representative Anderson, your bill changes the world. And for that bill, I thank you.'
'You put a lot of work into the bill, but you also ensure that it's not an unfunded mandate. You make sure that money is appropriated in this good bill. I really appreciate what you are doing to eliminate the burden for families,' said Marie Paule Woodson, D-Hollywood.
The program will run through Florida State University, with the hopes to further expand it to other universities here in the state.
'My hope for this is that over the next year or two, the pilot that's run through FSU will be very successful, and then our other universities that are members of the consortium like the University of Florida, USF, University of Miami and others can then bring this model to their university and then all coordinate and collaborate on the research,' Anderson said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Atlantic
8 hours ago
- Atlantic
The Future of Alzheimer's Diagnosis Is Now
A patient enters her general practitioner's office for a routine checkup. She is 65 years old, and—knock on wood—in good health: walking outside every morning, eating a thoughtful diet, and reading voraciously. All of this she naturally tells her doctor during the visit. However, lately she's been forgetting things here and there. Nothing major, she thinks. It's just a normal part of getting older. So this small detail she keeps to herself. But by holding on to that detail, the patient is also putting off a conversation that could change the course of her life as well as her family's. Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer's disease in the United States—a number that is expected to almost double in the next few decades. The fear that talking about it will lead to a road of invasive procedures, life-changing diagnoses, and painful choices is all too common. However, new scientific developments in diagnostics have been made so medical experts can help diagnose or rule out Alzheimer's disease sooner, and more easily, than ever before with a simple blood test. In this new era, patients can rule out the disease as a diagnosis or talk to their doctors about care options and plan with their families if they receive a diagnosis. When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future Brandy Matthews Vice President of Global and U.S. Medical Affairs for Eli Lilly and Company 'We have to overcome this barrier of stigma,' says Brandy Matthews, M.D., FAAN, vice president of global and U.S. medical affairs for Alzheimer's disease at Eli Lilly and Company, 'and then the reinforcement of the myths [so] that people will raise their hand when they begin to experience changes in their memory and thinking.' In addition to the laboratory developed tests that are already available and developed under the Clinical Laboratory Improvement Amendments (CLIA) to aid in Alzheimer's disease diagnosis, the FDA recently cleared the first in vitro diagnostic (IVD) blood biomarker test. These tests can be administered to symptomatic patients as part of a cognitive workup. 'The fact that there's been a recent FDA clearance for a blood biomarker in Alzheimer's disease is really critical and really big and I think will be a sort of a monumental shift in how we diagnose Alzheimer's disease,' says Anthony 'Nino' Sireci, M.D., MSc, senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company. The work of developing new technology to diagnose a disease is painstaking and slow, but these breakthroughs are essential for patients. These advances not only offer hope to millions but also provide researchers like Matthews and Sireci with a profound sense of purpose. 'When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future, to engage in lifestyle modifications, and to explore options for therapies that may target their symptoms or the underlying pathology of the disease,' says Matthews. Way back in 1906, the German neuropathologist Alois Alzheimer identified what he called 'an unusual disease of the cerebral cortex' marked by symptoms of memory loss. Using newly available technology, he identified two key pathological proteins in the neurons of his patients' brain cells: Beta-amyloid and tau. Beta-amyloid and tau are proteins produced naturally in the body. In patients with Alzheimer's disease, beta-amyloid starts to clump together, creating plaques between brain cells, while tau twists together into tangles inside brain cells. 'They are involved in a cascade of changes that happen in the brain, presumably initially with amyloid plaque accumulation, followed by tau tangle accumulation, leading to the dysfunction of the brain cells and then eventually neurodegeneration or shrinking of the brain. That results in the symptoms of Alzheimer's disease,' says Matthews. To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly Beta-amyloid plaques and tau tangles are the cause of the disease, but for nearly a century following their initial discovery, they could be identified only posthumously. This changed in 2002, when scientists identified amyloid plaque in the brain of a patient with a PET scan for the first time, using an imaging agent approved by the FDA in 2012. In 2022, the FDA cleared its first biomarker test measuring the presence of beta-amyloid in cerebrospinal fluid (CSF), drawn during a lumbar puncture (also known as a spinal tap). 'Modified fragments of those proteins are released into the cerebrospinal fluid,' says Sireci. 'And so those become some of the biomarkers that you measure in CSF.' While effective tools and necessary parts of the diagnostic process, PET scans and spinal taps are invasive and not always readily available, depending on where patients are located. This is where blood biomarkers come in, because beta-amyloid and tau aren't released only into CSF. 'Some of them actually leak out into the blood in super small quantities,' says Sireci. 'And that's what we use as the basis for identification of blood biomarkers in patients with Alzheimer's disease.' The traces found in these tests are smaller and harder to identify than the ones found in CSF. One challenge has been innovating over years to make blood test more closely resemble CSF – a major breakthrough developed over years of challenging work. And such tests require patients access and provider experience. In an ideal world, a simple blood sample could be collected at any doctor's office, even in rural or underserved communities, and sent to a major reference lab where, combined with the patient's initial cognitive assessment, it could provide information to help the treating physician to diagnose Alzheimer's disease without the need for additional confirmatory testing. That would vastly expand access to timely diagnosis. But there is still a lot of work to do between the clearance of a medical technology and its implementation. 'The obstacles now are not scientific,' says Sireci. 'Medicine is a logistical effort.' Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big. Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly 'It's implementation,' he says. 'Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big.' But with any new diagnostic tools come questions. Are physicians educated in how to understand the results? Are they confident in those results? And once they are, are they actually able to order the test at scale from high quality labs? It's about quality and it's about access. And that's only on the medical side. What about patients? Will insurers reimburse the tests so that patients are not faced with high out-of-pocket costs? Will patients embrace them? Sireci is optimistic about both possibilities. A recent survey by the Alzheimer's Association found that 91 percent of patients would want a blood biomarker test if it were made available to them. A readily available blood biomarker test gives doctors and patients a tool to aid in accurate and timely diagnosis. That patient who walked into her general practitioner's office? She would undergo a routine cognitive exam (a recommended standard for all patients 65 and older). She would have an honest conversation with her doctor about changes she might be perceiving in her brain function, however slight. And if the doctor thought it was necessary, a referral to a specialist for a simple blood test would be administered to help inform next steps. Then, unlike in the decades when Alzheimer's disease could be diagnosed only symptomatically or after an invasive procedure, the doctor would lead her in an informed, fact-based discussion—right away. From that conversation, the patient could undergo a PET scan or CSF testing to confirm or rule out the diagnosis if necessary. 'To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged,' says Sireci, 'but also [that] they're not waiting years for a diagnosis, which unfortunately is what's happening today.' We're moving the needle for patients and giving physicians another very powerful tool to combat this disease. Anthony 'Nino' Sireci M.D., Senior Vice President of Diagnostics Development at Lilly This is crucial because Alzheimer's is a progressive disease. Timing is critical. The earlier a patient is diagnosed, the more time they have for planning, which could include treatment options a patient has available to them. They can set themselves up for counseling, talk to their families, and could choose to begin medical intervention. 'We've learned over time that initiating therapy in the earlier stages of disease can have greater impact,' says Matthews. 'And even within those early symptomatic stages of disease, there's evidence, across a class of medicines, that the earliest stages of early symptomatic Alzheimer's disease may demonstrate the greatest benefit of new therapies.' For Sireci, who has experience with Alzheimer's disease both as a doctor and as the family member of a patient, the most gratifying aspect of his research is knowing that it can help shorten what he calls the 'diagnostic odyssey.' 'Even if that just means getting the conversation to happen for the physician faster than it would've, then I'm happy,' says Sireci. 'That's a really big deal. We're moving the needle for patients and giving physicians another very powerful tool to combat this disease.' The Future of Alzheimer's Diagnosis Is Now Hear more from Brandy Matthews, Vice President of Global and U.S. Medical Affairs at Eli Lilly and Company, on the future of Alzheimer's diagnosis. learn more
Yahoo
14 hours ago
- Yahoo
Mom Thought She Just Had Dry Skin. Months Later, She Had Hole 'The Size of a Quarter' in Her Nose After Skin Cancer Diagnosis
Amanda Anderson, 43, received the diagnosis in June after first noticing a "small irritated spot" on her nose in January NEED TO KNOW Amanda Anderson, a mother of four, discovered a small spot on her nose that she thought was dry skin But after several appointments, doctors determined it was actually basal cell carcinoma She underwent surgery to remove the spot and documented her journey online A mother of four thought she just had a bit of dry skin on her nose, months before receiving a shocking diagnosis. Amanda Anderson, 43, from Layton, Utah, first noticed she had a small spot on the side of her nose in January of this year; however, she wasn't initially concerned, as she said her skin often gets dry during the winter months, per SWNS. Anderson ended up getting the spot checked out just to be on the safe side and was given a cream. When the spot came back and started to bleed and scab, Anderson booked another appointment with the doctor, only to be told she didn't have anything to worry about. After having a gut feeling that something was wrong, Anderson went to another medic, who then booked her in for a biopsy in June, before the results came back as basal cell carcinoma on June 23. She was scheduled for surgery three days later to remove the spot. Per the Mayo Clinic, "Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells — a type of cell within the skin that produces new skin cells as old ones die off." "Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as your head and neck," the site adds. Anderson has documented her skin cancer journey on TikTok, writing in the caption of one of her videos, "WEAR YOUR SUNSCREEN!!" "I had a small irritated spot on my nose for 6 months. I finally went into the dermatologist. It wasn't a huge shock to find out it was Basal Cell Carcinoma," she added. "Getting it removed was a HUGE shock. I had no idea what I was getting into!" Anderson wrote, sharing in the clip that she'd had Mohs surgery, and that medics ended up having to do three passes. She wrote over the video per the AP, "It was sooo much bigger than I was expecting," confirming she had 50 plus stitches. The clip featured multiple images showing Anderson's cancer journey, including her having a hole cut from her nose to remove all the cancer cells. The Mayo Clinic describes Mohs surgery as "a procedure used to treat skin cancer," adding, "This surgery involves cutting away thin layers of skin. Each thin layer is looked at closely for signs of cancer. The process keeps going until there are no signs of cancer." "The goal of Mohs surgery is to remove all of the skin cancer without hurting the healthy skin around it. Mohs surgery allows the surgeon to be sure that all the cancer is gone. This makes it more likely that the cancer is cured. It reduces the need for other treatments or more surgery," the site states. Anderson recalled of her initial symptoms, "It was just a little dry spot on the side of my nose," adding, "With it being the winter it's common to have dry patches. I wasn't super concerned at the beginning," per SWNS. Anderson — whose father, Kirk Romney, 66, has also had skin cancer, and has had over 17 Mohs surgeries to remove cancerous cells from his face, neck and shoulders — insisted, "When I noticed the spot at first I wasn't too concerned." "It's typical to get dry patches because of the weather here in Utah," she added. Anderson said of receiving the skin cancer diagnosis, "It's hard to hear. It's on my face and as a woman we do everything we can to make sure our faces look as good as possible." "I'm obsessed about sun cream and shade - I have been my whole life," she added. "So it was a bit of a gut punch." Anderson added of doctors removing part of her nose to get the cancer out, "It was about the size of a quarter. They cut above and below the hole and fold the skin over." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Anderson, who continues to keep her followers updated regarding her skin cancer journey on TikTok, confirmed she won't need further treatment, but will have to have check-ups every six months. She said of now wanting to warn others, "The damage is done when you're young. I encourage my daughters to put sun cream on underneath their makeup." "I'm trying to build healthy habits in my kids," Anderson added. "People don't realize you can get sunburnt through the window of a car. We have to take care of our skin like you would your teeth. Skin cancer is so preventable." PEOPLE has reached out to Anderson for an update on her recovery. Read the original article on People Solve the daily Crossword
Yahoo
14 hours ago
- Yahoo
Mom Thought She Just Had Dry Skin. Months Later, She Had Hole 'The Size of a Quarter' in Her Nose After Skin Cancer Diagnosis
Amanda Anderson, 43, received the diagnosis in June after first noticing a "small irritated spot" on her nose in January NEED TO KNOW Amanda Anderson, a mother of four, discovered a small spot on her nose that she thought was dry skin But after several appointments, doctors determined it was actually basal cell carcinoma She underwent surgery to remove the spot and documented her journey online A mother of four thought she just had a bit of dry skin on her nose, months before receiving a shocking diagnosis. Amanda Anderson, 43, from Layton, Utah, first noticed she had a small spot on the side of her nose in January of this year; however, she wasn't initially concerned, as she said her skin often gets dry during the winter months, per SWNS. Anderson ended up getting the spot checked out just to be on the safe side and was given a cream. When the spot came back and started to bleed and scab, Anderson booked another appointment with the doctor, only to be told she didn't have anything to worry about. After having a gut feeling that something was wrong, Anderson went to another medic, who then booked her in for a biopsy in June, before the results came back as basal cell carcinoma on June 23. She was scheduled for surgery three days later to remove the spot. Per the Mayo Clinic, "Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells — a type of cell within the skin that produces new skin cells as old ones die off." "Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as your head and neck," the site adds. Anderson has documented her skin cancer journey on TikTok, writing in the caption of one of her videos, "WEAR YOUR SUNSCREEN!!" "I had a small irritated spot on my nose for 6 months. I finally went into the dermatologist. It wasn't a huge shock to find out it was Basal Cell Carcinoma," she added. "Getting it removed was a HUGE shock. I had no idea what I was getting into!" Anderson wrote, sharing in the clip that she'd had Mohs surgery, and that medics ended up having to do three passes. She wrote over the video per the AP, "It was sooo much bigger than I was expecting," confirming she had 50 plus stitches. The clip featured multiple images showing Anderson's cancer journey, including her having a hole cut from her nose to remove all the cancer cells. The Mayo Clinic describes Mohs surgery as "a procedure used to treat skin cancer," adding, "This surgery involves cutting away thin layers of skin. Each thin layer is looked at closely for signs of cancer. The process keeps going until there are no signs of cancer." "The goal of Mohs surgery is to remove all of the skin cancer without hurting the healthy skin around it. Mohs surgery allows the surgeon to be sure that all the cancer is gone. This makes it more likely that the cancer is cured. It reduces the need for other treatments or more surgery," the site states. Anderson recalled of her initial symptoms, "It was just a little dry spot on the side of my nose," adding, "With it being the winter it's common to have dry patches. I wasn't super concerned at the beginning," per SWNS. Anderson — whose father, Kirk Romney, 66, has also had skin cancer, and has had over 17 Mohs surgeries to remove cancerous cells from his face, neck and shoulders — insisted, "When I noticed the spot at first I wasn't too concerned." "It's typical to get dry patches because of the weather here in Utah," she added. Anderson said of receiving the skin cancer diagnosis, "It's hard to hear. It's on my face and as a woman we do everything we can to make sure our faces look as good as possible." "I'm obsessed about sun cream and shade - I have been my whole life," she added. "So it was a bit of a gut punch." Anderson added of doctors removing part of her nose to get the cancer out, "It was about the size of a quarter. They cut above and below the hole and fold the skin over." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Anderson, who continues to keep her followers updated regarding her skin cancer journey on TikTok, confirmed she won't need further treatment, but will have to have check-ups every six months. She said of now wanting to warn others, "The damage is done when you're young. I encourage my daughters to put sun cream on underneath their makeup." "I'm trying to build healthy habits in my kids," Anderson added. "People don't realize you can get sunburnt through the window of a car. We have to take care of our skin like you would your teeth. Skin cancer is so preventable." PEOPLE has reached out to Anderson for an update on her recovery. Read the original article on People Solve the daily Crossword